Generating a Codon-Optimized Gene Construct to Aid SSGCID in their Structural Elucidation Efforts

On going
Start date
Start stage
Hit ID

Praziquantel was discovered 40 years ago and remains the only available treatment for schistosomiasis, a disease that affects 240 million people globally. Through WIPO Re:Search, investigators from Seattle Childrenā€™s Research Institute and the NIAID-funded Seattle Structural Genomics Center for Infectious Disease (SSGCID) are working to solve the crystal structure for Schistosoma HMG-CoA reductase (SmHMGR), a promising drug target. To support these efforts, MSD* scientists developed and shared codon-optimized SmHMGR gene constructs for expressing the SmHMGR protein and solving its crystal structure. With a crystal structure, Dr. Conor Caffrey at the University of California, San Diego plans to carry out rational drug design and optimization of SmHMGR inhibitors.

*MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA